Carisma Therapeutics, Inc. (CARM)

Carisma Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	56.52	77.61	24.19	162.64	55.39	48.14
Short-Term Investments	0	0	27.8	0	0	0
Cash & Cash Equivalents	56.52	77.61	52	162.64	55.39	48.14
Cash Growth	-59.34%	49.25%	-68.03%	193.63%	15.06%	-4.56%
Receivables	0	0	0	24.49	0	0
Other Current Assets	4.44	2.87	2.6	18.48	7.48	6.31
Total Current Assets	60.95	80.47	54.59	205.61	62.87	54.45
Property, Plant & Equipment	12.7	8.94	13.45	0.04	0.12	0.24
Long-Term Investments	0	0	0	0.02	0.02	0
Goodwill and Intangibles	0	0	0	27.76	59.46	59.46
Other Long-Term Assets	0.14	0.15	4.11	7.32	0.35	0.22
Total Long-Term Assets	12.84	9.08	17.56	35.14	59.96	59.92
Total Assets	73.8	89.55	72.15	240.75	122.82	114.37
Accounts Payable	2.17	3.93	1.73	2.85	3.1	1.9
Deferred Revenue	46.19	46.41	47.46	1.5	3	0
Current Debt	3.86	1.94	4.6	0	0	0
Other Current Liabilities	-39.08	-36.37	-34.12	7.22	11.95	6.62
Total Current Liabilities	13.14	15.91	19.67	11.57	18.05	8.52
Long-Term Debt	3.63	1.19	35.57	0	0	0
Other Long-Term Liabilities	46.13	45.93	51.78	57.47	114	132.55
Total Long-Term Liabilities	49.76	47.11	87.35	57.47	114	132.55
Total Liabilities	62.9	63.02	107.02	69.04	132.05	141.07
Total Debt	7.49	3.12	40.16	0	0	0
Debt Growth	36.89%	-92.22%	-	-	-	-
Retained Earnings	-264.08	-245.1	-158.22	-316.26	-315.92	-293.52
Comprehensive Income	0	0	-0.04	0	0	0
Shareholders' Equity	10.9	26.53	-157.07	171.71	-9.23	-26.7
Net Cash / Debt	49.02	74.48	11.83	162.64	55.39	48.14
Net Cash / Debt Growth	-63.29%	529.50%	-92.72%	193.63%	15.06%	-4.56%
Net Cash Per Share	1.20	2.22	5.56	17.84	9.37	10.59
Working Capital	47.81	64.56	34.92	194.04	44.82	45.93
Book Value Per Share	0.27	0.79	-73.81	18.84	-1.56	-5.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).